MyFinsight
Home
Blog
About
Gross proceeds from
issuance of common stock...
$3,585,308
Gross proceeds from
issuance of common stock...
$1,861,921
Gross proceeds from
issuance of common stock...
$217,500
Net cash provided by
financing activities
$2,079,421
(-81.15%↓ Y/Y)
Canceled cashflow
$3,585,308
Net change in cash
$1,109,422
(-13.46%↓ Y/Y)
Canceled cashflow
$969,999
something is missing
-$3,585,308
Prepaid and other
current assets
-$495,501
(-1040.60%↓ Y/Y)
Change in the fair value
of warrant...
$29,245
(-74.98%↓ Y/Y)
Accrued interest,
related parties
-$18,845
(89.40%↑ Y/Y)
Due to related party
$6,844
(106.74%↑ Y/Y)
Depreciation
$468
(-37.01%↓ Y/Y)
Net cash used in
operating activities
-$969,999
(89.19%↑ Y/Y)
Canceled cashflow
$550,903
Net loss
-$1,407,259
(-556.86%↓ Y/Y)
Accounts payable and
accrued expenses
-$102,128
(95.00%↑ Y/Y)
Forgiveness of unrelated
vendor payables
$11,515
(-99.46%↓ Y/Y)
Back
Back
Cash Flow
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)
source: myfinsight.com